Beletalent Pharmaceutical

Beletalent Pharmaceutical is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative small molecule precision medicines for oncology. The company focuses heavily on the RAS signaling pathway, with a robust pipeline targeting various KRAS mutations including G12C, G12D, and G12V, as well as upstream regulators like SOS1 and SHP2. Their lead candidate, BLT-1822, is a potent KRAS G12C inhibitor currently undergoing clinical evaluation for advanced solid tumors. By leveraging its expertise in medicinal chemistry and structure-based drug design, Beletalent aims to provide effective therapeutic solutions for patients with difficult-to-treat cancers.